#POLB Poolbeg Pharma PLC – Letter to Shareholders – 2025 a year of progress December 18, 2025 – Posted in: Poolbeg Pharma (POLB)

18 December 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, publishes an end of year letter from the Company’s Executive Chair, Cathal Friel, providing an overview of the significant progress made by the Company in 2025 and outlook for 2026.   Dear Shareholders,   As 2025 draws to a close, we wanted to reflect on the substantial progress made by Poolbeg this…

Continue reading